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Abstract
Background
While several papers have highlighted a lack of evidence to scale social innovations in
health, fewer have explored decision-maker understandings of the relative merit of different
types of evidence, how such data are interpreted and applied, and what practical support is
required to improve evidence generation. The objectives of this paper are to understand (1)
beliefs and attitudes towards the value of and types of evidence in scaling social innovations
for health, (2) approaches to evidence generation and evaluation used in systems and policy
change, and (3) how better evidence-generation can be undertaken and supported within
social innovation in health.
Methods
Thirty-two one-on-one interviews were conducted between July and November 2015 with
purposively selected practitioners, policymakers, and funders from low- and middle- income
countries (LMICs). Data were analysed using a Framework Analysis Approach.
Results
While practitioners, funders, and policymakers said they held outcome evidence in high
regard, their practices only bear out this assertion to varying degrees. Few have given sys-
tematic consideration to potential unintended consequences, in particular harm, of the pro-
grams they implement, fund, or adopt. Stakeholders suggest that better evidence-
generation can be undertaken and supported within social innovation in health by supporting
the research efforts of emerging community organizations; creating links between practition-
ers and academia; altering the funding landscape for evidence-generation; providing
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responsive technical education; and creating accountability for funders, practitioners, and
policymakers.
Conclusion
How better evidence-generation can be undertaken and supported within social innovation
in health is a previously under-operationalised aspect of the policy-making process that
remains essential in order to refrain from causing harm, enable the optimization of existing
interventions, and ultimately, to scale and fund what works.
Introduction
In recent years, there has been a proliferation of projects, organizations, businesses, and
research studies aimed at solving problems stemming from the inaccessibility or lack of
health care facing millions of people around the world. These efforts have developed
‘social innovations,’ defined by the editors of the Stanford Social Innovation Review as
“the process of inventing, securing support for, and implementing novel solutions to
social needs and problems.”[1] Most studies examining how evidence is used to advance
social innovations in health have found discrepancies between ideal and actual practice.
Milat et al. found that while research evidence is used in decision-making, its contribution
was limited by the lack of research on effectiveness and cost-effectiveness [2]. These find-
ings were echoed by Yamey et al. who interviewed implementation experts purposively
selected for their expertise in scaling-up health interventions in low- and middle- income
countries (LMICs), and found that a major barrier to effective implementation was inade-
quate research [3]. A systematic review of barriers and facilitators of evidence usage by
policymakers in any field found that the primary barrier was poor access to quality, rele-
vant and timely research [4].
Though research on the scaling, i.e. widespread replication and/or adoption [5], of social
innovations in health exists [6–10], such literature notes only that evidence plays a role in
scale-up—it does not explore what types of data are most useful and persuasive to policymakers
and funders nor how these data are interpreted and applied. Consequently, practitioners work-
ing in the field (i.e. health service providers, NGO workers) are left with little guidance on how
to rigorously and efficiently assess effectiveness and feasibility of their intervention [8, 9, 11].
Moreover, these papers typically focus on a subset of actors (e.g. only implementation experts)
and have not fostered a conversation across all actors required to scale programs. Though the
value of evidence generation is well-documented—good evaluation enables the identification
of harms [12] as well as the optimisation of existing interventions [13]—how policymakers,
funders and practitioners might work together to better create and use it remains under-
explored.
Given this, the objectives of this paper are to:
1. Understand the beliefs and attitudes of policymakers, practitioners, and funders toward the
value and types of evidence for scaling social innovations for health
2. Understand practitioner, policymaker and funder approaches to generating evidence for
systems and policy change
3. Understand how better evidence-generation can be undertaken and supported within social
innovation in health.
Supporting Evidence Generation & Use within Social Innovation in Health
PLOS ONE | DOI:10.1371/journal.pone.0170367 January 26, 2017 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
Methods
Study design
As the focus of this inquiry was to provide rich descriptions of complex phenomena, illumi-
nate the experience of actors with widely differing stakes and roles, and generate hypotheses
about potential solutions, qualitative methods were used [14]. One-on-one interviews were
conducted via Skype or telephone to increase participation and enable sampling from a wide
range of geographies. The Department of Social Policy and Intervention Research Ethics Com-
mittee (DREC) provided ethics approval in accordance with the procedures established by the
University of Oxford. Participants were approached by email and provided written consent to
participate and for the researchers to publish findings. Three of those contacted declined to
participate; all three said they did not feel qualified to comment on the subject. The study was
reported in accordance with the Consolidated criteria for reporting qualitative research
(COREQ) checklist [15].
Participants and setting
Thirty-two interviews were conducted between July and November 2015. In order to under-
stand a range of viewpoints, we targeted three categories of stakeholders: practitioners, policy-
makers, and funders. Health practitioners were sampled via the network of a prominent social
entrepreneurship foundation that identifies and supports high-performing innovators (i.e.
strong strategic partnerships, scalable model, diversified funding base,>1 million USD operat-
ing budget etc.). Policymakers and funders were purposively selected for their experience
working with participating practitioners and, in the case of funders, their eminence in health-
care financing (>2 billion USD direct grantee support per year). Participants were classified
by their primary present occupation; several participants had expertise in one of the other
areas (i.e. practitioners who later became policymakers). Recruitment was on a first come,
first served basis.
Procedure
Interviews lasted 30–45 minutes and were predominantly conducted by MB and JT. Neither
MB nor JT had a prior relationship with those they interviewed and participants likewise had
little knowledge of the interviewers. Both MB and JT were doctoral students at the time of the
study and both had previous experience working in healthcare in LMICs. A topic guide tai-
lored to each type of stakeholder was used, which included perceived value of research, under-
standing of study design, experiences working with the various groups, and suggestions for
improvement. The guide was piloted on the first two interviews of each stakeholder type and
subsequently refined. Interviews were audio recorded and transcribed verbatim (see S1 Dataset
for anonymised transcripts). No repeat interviews were conducted; no gratuity was offered to
participants.
Analysis
Data were analysed using a Framework Analysis Approach. This is a matrix-based approach to
qualitative data analysis. It involves analysing verbatim transcripts for themes based on a com-
bination of a priori issues and emergent themes [16]. This was chosen over more inductive
methods because the aim of the study was to both achieve pre-set objectives and inductively
explore respondent accounts.
MB and JT became familiar with the data by reading through transcripts while listening to
audio recordings. The two researchers independently coded the same five transcripts before
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meeting to discuss key themes and draft an initial coding framework. Both researchers inde-
pendently coded five further transcripts using this framework before conferring to refine it.
This process was repeated until no new themes emerged and the final coding framework was
finalised (see S1 Appendix for final coding tree and definitions).
A qualitative data-management package (QSR NVivo version 10.2.1) [17] was used for cod-
ing and analysis. At the conclusion of coding, data were summarised into a series of matrices,
one for each theme, with one row per participant and one column per code. The matrices were
analysed by making connections within and between codes and participants; this process was
influenced by a priori research objectives and by concepts generated inductively from the data
[18].
Validity
Each transcript was double coded by MB and JT who met at regular intervals to compare clas-
sification of supporting quotes into codes, discuss deviant cases, and resolve discrepancies in
interpretation. A draft of the paper was returned to participants for comment and/or correc-
tion on quotes and feedback on the findings.
Results and Discussion
14 practitioners, 12 funders, and 5 policymakers working in eight LMICs were interviewed
(Table 1). There were no notable discrepancies in data interpretation between co-researchers.
1. Beliefs and attitudes about evidence
Practitioners. Practitioners conceived of the utility of evidence in three primary ways:
I. Research as an accountability mechanism
Several practitioners highlighted outcome evaluations, which measure the change that has
occurred as result of a programme, as a way to ensure recipients of their program benefitted as
Table 1. Participant Characteristics.
Practitioners Funders Policymakers Total
N (%) N (%) N (%) N (%)
Gender Male 10 (71) 9 (75) 5 (83) 24 (75)
Female 4 (28) 3 (25) 1 (17) 8 (25)
Role Founder /Leader 6 (93) 3 (25) N/A 16 (50)
M&E* expertise 3 (21) 0 (0) 0 (0) 3 (9)
Focus^ Specific Country 7 (50) 0 (0) 6 (100) 13 (40)
International 5 (36) 12 (100) N/A 17 (53)
Developing Country Focus 12 (86) 12 (100) 5 (83) 29 (91)
Occupation Manager/ Executive 12 (86) 11 (92) N/A 23 (72)
Analyst 2 (14) 2 (17) N/A 4 (13)
Researcher/ Academic 3 (21) 0 (0) N/A 3 (9)
Clinician 4 (29) 0 (0) N/A 4 (13)
Minister 0 (0) 0 (0) 6 (100) 6 (19)
*M&E: Monitoring and Evaluation
^ Individuals worked in a large range of geographic regions: Caribbean; Central and South America; Central, Southern, and East Asia; East, West, Central
and Southern Africa; and the Middle East and North Africa.
doi:10.1371/journal.pone.0170367.t001
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intended. They pointed out the necessity of measuring programme effectiveness as a natural
extension of their obligation to provide essential services.
Research is a tool of justice. . .how are we holding ourselves accountable . . . to whether or
not ideas that we have are helping anyone or hurting people. If we don’t measure, we don’t
know. (P2)
One practitioner, however, was sceptical of the alignment between what practitioners
claimed they believed about research and the rigor with which they follow through on these
convictions:
When you really get down to it. . .no one really wants their work to be looked at with a fine-
toothed comb. (P12)
II. Research as an opportunity to refine service delivery.
Process evaluations, which examine the implementation of an intervention, were cited as a
means to identify “where [services] can be improved” (P5, P6). For example, one practitioner
was able to use the variability between programme sites to refine operations in places that were
underperforming:
. . . sites cross-share data [enabling them] to both critique and ask questions as to why their
retention numbers are so high or so low, what kinds of things are they doing that might be
different. . . (P10)
III. Research as a means of fulfilling expectations of funders and policy-makers.
Another group cited external pressure as the primary reason to conduct outcome and oper-
ational research. While they saw research as a burden (“we tend to do what we sort of have to
do,” P1) or were passive decision-makers in conducting research (“we define our success by
meeting our targets as determined by whatever funder’s proposal or whatever funder’s require-
ments are,” P12), others viewed building a joint research agenda as a positive, synergistic pro-
cess. This is especially true of those practitioners working closely with the Ministry of Health
(MOH) in their respective countries. By aligning or jointly developing research questions with
the MOH, practitioners were better placed to scale nationally (P11) and create the trust neces-
sary for novel approaches:
If we had gone into these areas with the Ministry and said: “Oh we actually want to do
something that is completely different than your current national policy,” the Ministry
would have blocked it. . .the research we did together. . .opened the door to. . .joint innova-
tion. (P2)
While practitioners are in favour of research, they are not convinced that funders and pol-
icy-makers use it to make decisions. One practitioner declared, “a huge amount of interven-
tions that happen in the global health space. . .are scaled in an evidence free zone” (P2). Several
practitioners believe funders have a groupthink dynamic and suggested personal relationships
often trump evidence:
We just got a call from [a funder] on Friday, potentially giving us a million dollars to launch
this [program]. . . as soon as one drops, others will drop. . . (P4)
Supporting Evidence Generation & Use within Social Innovation in Health
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As in Yamey [3], practitioners asserted that funders are more moved by stories or personal
connections than rigorous counterfactuals, preferring emotional appeals (e.g. individual testi-
monies) to population-level data:
I mean we do report to donors. . .[but] that’s much more. . . stories than it is an analysis.
(P1)
Because if someone said, “give us evidence” we bring out someone who can tell a power-
ful personal story. . .there’s a donor base that responds to [anecdotes] and doesn’t respond
to “. . . RCTs and . . . confidence intervals”. (P4)
While some practitioners conceded that this trend was changing—“in the coming years
organisations that are not [becoming] evidence-based, they [will] face challenges in raising
resources to support their work” (P14)—most felt that funders in particular did not under-
stand evaluations well enough to critically appraise study designs and evidence quality:
Few people understand. . .the difference between the clustered-randomized trial and one
that’s just randomized. (P6)
Funders. While funders say they hold outcome evidence in high regard, this is often not
translated into practice. Funders spoke of the importance of external evaluations (F4), strong
data systems (F1) and ultimately “creating an impact” (F4). Yet for several of the funders, espe-
cially those from family and corporate foundations, identification of potential grantees is not
systematic and often based on referrals through "networks" of trusted partners (F1, F2, F10,
F11). While most stressed that referrals guarantee closer scrutiny and not funding; two admit-
ted that “it’s a bit of an echo chamber” (F2) and that “the deck is [potentially] stacked against”
organisations without connections (F10). Moreover when asked how they evaluate potential
organisations, funders cited organisational health metrics (F2), “visionary” leadership (F11),
or novelty, rather than outcome evaluations:
Sometimes it’s just a gut feeling. It might be something very new. It might be untested, but
you kind of have a sense that there’s real excitement. (F9)
Even when funders cited clear outcome metrics (e.g. “DALYs [disability adjusted life years]
averted, return on investment,” F7) they admitted they did not critically engage with the
underlying studies. Several had misunderstandings of technical details in evaluation research
or admitted research expertise was lacking on their teams:
Frankly, we don’t have program officers who are extensively trained in M&E. (F7)
Others questioned whether, as funders, they could ever adequately assess a given
programme:
I think one of the things you have to accept when you’re funding projects. . .is that reporting
on an application to its owner is an honour-based system. (F5)
There was recognition that funders could be driving the “evidence-free zone”:
Most organisations don’t effectively measure their own impact because the funders don’t
ask them to and the funders don’t ask them to because they don’t really understand it well
Supporting Evidence Generation & Use within Social Innovation in Health
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enough or it’s . . . not in their best interests to ask for it. . .this sector has simply been . . .
“put hopeful money in and be unclear on what you get out”. (F1)
That said, funders are not a homogenous group, and several echoed practitioners on the idea
that times were changing and had clear ideas about the types of evaluations they would like to see:
We feel like [strong M&E] is now required by the field to scale and it’s just healthy. . .to
know what impact you’re having. (F11)
We’d love to see more organisations pay attention to meaningful, concrete quantifica-
tion of their work (e.g. pilot, larger trials). . . (F3)
While some funders were very understanding of the challenges faced by organisations to
generate quality evidence—noting the difficulty of gathering real time data (F6) or the chal-
lenge of doing qualitative research without “sufficient money” (F9)—other funders expressed
their own frustrations with NGO and health service practitioners:
Many organisations either don’t think very systemically about what they should measure to
either show an impact or. . .how to iterate. . .their approach. Often, [it’s] implementation of
an idea without clear testing beforehand. (F3)
We would like obviously the grantees to have a strong theory of change. . .for that to be
laid out in terms of a results framework. . .I think that’s where a lot of the grants frankly are
lacking. (F7)
Policymakers. Policymakers also mostly held evidence in high regard—e.g. “We’ll never
take things on that haven’t worked yet,” (M6)—but were much more likely to be explicit about
the types of evidence they valued to identify interventions to scale. As one Director General of
a MOH in West Africa explained:
New interventions are basically selected based on. . . if an intervention is proven to be effec-
tive. . .especially in similar settings, and if there are very strong evidences. (M3)
One policy-maker however, admitted to not rigorously reviewing the evidence for solutions
implemented: “I think the [research] evidence of those things. . . I’m assuming that it’s already
known. . . but honestly I didn’t read anything recently.” (M5)
Consistent with earlier findings [7, 18], they revealed a preference for local evidence—“the
fact that it works in Bangladesh doesn’t mean that it works in [country name]” (M2)—how-
ever, there was also a willingness to pilot ideas from different places:
There are some interventions that you need to do a pilot . . . and if those interventions are
proven to be effective after the pilot, then you go for them. (M3)
Policy-makers also recognised the challenges of generating evidence and did not always
demand that evidence for policy and program interventions be generated with the same level
of rigor as that required in clinical trials for drugs and diagnostics:
When we find out that the benefits outweigh the risks, we sometimes say to them, “Go”
without necessarily having the highest of all evidence, [a randomised trial], and then we
monitor and rule on that as we go. (M6)
Supporting Evidence Generation & Use within Social Innovation in Health
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Though, in keeping with previous literature [2, 4], policymakers noted that evidence is only
one factor when making a scale-up decision, conceding that interventions aligned with national
priorities (M2) or introduced by trusted colleagues (M3) are more likely to considered. They
roundly rejected, however, the idea that personal ties were sufficient to bring something to scale:
What you bring—the quality of product that you bring—is very important, the amount of
evidence, and the evidence of the impact this intervention had in other countries is very
important. So, it’s not only the question of who brings it, but what contribution could it
make [based on] the evidence. (M2)
2. Approaches to evidence generation
Practitioners face several barriers in undertaking research. A central tension is striking the
right balance between rigor and operational relevance. While practitioners conceded that
exacting methods would make their results more convincing—“in an ideal world I would want
to see . . . more academic rigor. . . to really figure out how . . . you prove this” (P3)—many
expressed concerns that such “over the top” designs could “slow [them] down” (P3, P2, P14).
Compounding this issue is the difficulty of finding accessible technical expertise. Almost
every practitioner had a technical query they could not answer (see S1 Dataset). Practitioners
also highlighted human resource shortages (P14), difficulty identifying useful resources (P10),
and above all, the expense they perceive to be associated with rigorous research: “my first eval-
uation cost three times my [programme] budget. Now that is wrong” (P4).
Perhaps as a result, most of the organisations interviewed, despite being sampled from a
group recognised as high performing (i.e. strong strategic partnerships, scalable model, diver-
sified funding base), have never conducted longitudinal research, used counterfactuals, or
identified which parts of their program mediate its effects
More troubling is the finding that practitioners, funders, and policymakers have given little
systematic consideration to potential unintended consequences of the programmes they
implement, fund, or adopt. While a small number were open about harms, the vast majority
did not have rigorous systems to measure harm, and several denied that harm was possible.
Two practitioners talked very explicitly about harm, one due to unintentional exposure to
environmental risks for staff and the other as a result of aggressive implementation leading to
burn out, reductions in quality of delivery and thus potentially endangering patients (P2, P10).
Both noted the role of constant data collection in being able to identify these damaging pat-
terns and stressed that recognising such pitfalls was “as important, if not more important” as
measuring programme success (P2).
Many more practitioners, however, were not able to articulate how their programmes mea-
sure potential harms:
That’s just a fascinating question. We have not dug in there. (P13)
There are no ‘checks and balances’ that we put in place other than following the already
predefined country rules and regulations. (P14)
A small number were vigorously defensive about their organisations, dismissing the possi-
bility of any ill effects or their severity—even after repeated probing:
I’m a little stuck to answer that. I think there’s times when we don’t always do our work as
well as we’d like but I think in the world of health, what we’re doing is. . .I’d hate to sound
self-righteous, but it’s fairly noble. (P9)
Supporting Evidence Generation & Use within Social Innovation in Health
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Funders fell into a similar taxonomy, with some denying it (“I actually think in this space
that’s not a serious issue,” F6) and most having failed to consider it systematically (F7):
Well, within the health space, we are really focused on the distribution of health services and
goods so in terms of the harm aspect we haven’t spent a lot of time thinking about that. (F11)
One difference is that, among those who had considered it, funders felt less likely to hear of
harm or empowered to stop harm than practitioners:
We also fund only people with really good monitoring systems in place so that untoward
consequences, unintended consequences, should be picked up fairly early. . . I don’t know
anybody who has a fool proof way of avoiding unintended consequence. (F1)
My parents have asked me, “Well, what does the foundation do in situations [where
harm has been caused]?” . . .and I don’t know. (F7)
3. Doing better: supporting evidence generation and use
While most enquiries into scale and evidence generation have only spoken to one set of stake-
holders and have thus collected a series of claims by one group about the failings of the other
[4, 19], by speaking with all groups concurrently we were able to convene a constructive dis-
cussion and guide the identification of areas in which actionable strategies for improvement
could be generated.
1. Supporting the research efforts of emerging organisations. Research is often side-
lined during the early stages of organisational development, despite its importance. Practition-
ers cited the importance of establishing data collection mechanisms in the early stage of a new
organisation as it is “costly” to compensate for poor or non-existent data down the line (P2,
P8). Yet, as one practitioner points out, young organisations face a catch-22 when attempting
to grow their programs and data systems:
It’s rough out there. . .community service organisations . . .don’t get funded because they
don’t have evidence, and they don’t have evidence because they don’t have the money or
the smarts. (P4)
There is also the tension between exacting evidence standards without ‴extinguishing’ innova-
tion and small community generated projects” (P4). Practitioners suggested prioritising identifi-
cation of promising early-stage health organisations and supporting them to create "meaningful
evidence. . .[when they] don’t have the human resources and the financial resource" (P4). This
includes “building the capacity of human resources” from LMICs, including local researchers
and practitioners, as a central part of measurement and implementation (P9).
2. Creating links between practitioners and academia. Practitioners and funders noted
that “academic research isn’t set up to match the most qualified investigators with implement-
ing organisations that are trying to take on [big] problems” (P2). While, for example, the Eco-
nomic and Social Research Council (UK) and other programs attempt this, all parties
suggested an additional formal mechanism for partnerships be created and supported.
Though organisations acknowledge that there are challenges in finding the right academic
fit—“culture shock” (P6), “misaligned priorities” (P2)—many touted the benefits that academic
expertise could bring: “[the academic team] made a control group. . .added measurements. . .
[assessed] the long-term impact. . .we use [those] results to do advocacy”(P5). While others
noted that an academic affiliation is typically required to receive ethics approval (P4).
Supporting Evidence Generation & Use within Social Innovation in Health
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Echoing the findings of Yamey [3], respondents noted that the comparably lower standing
of implementation science among researchers was a barrier to well-designed, applicable
research; raising the status of implementation science is imperative, especially to attract young
academics to the field (F8).
. . . one of the things they’re working on at Harvard [and Johns Hopkins] is. . .recognising
good, operational research as part of someone’s academic portfolio so that that gets
rewarded in the tenure system. (P9)
Even so, it was acknowledged that despite a few appointments based on these new criteria,
there was a long way to go to change the perception that success only comes via “hardcore first
and last author papers” (F8). A potential stopgap measure while this larger structural change
takes place would be for funding agencies to provide small stipends for academics to be “fel-
lows” (e.g. similar to IDEO) at global health NGOs (P6).
3. Change the funding landscape for evidence-generation. While universities are par-
tially responsible for structuring what type of research gets undertaken, the research grant-
making process, especially in the United States, is another driving force:
There are constraints on trying to get implementation science funded right now in the U.S.
. . . there’s no National Institute of Implementation Science. So, implementation science or
operations research is actually quite difficult . . .because it’s not obviously [funded] in one
place or another. (F8)
Some practitioners have found ways to "game the system" by finding academics who are
willing to give a portion of their time ("either as a donation or as a portion of their FTE [full
time equivalency]") However, because they are "not on traditional NIH [National Institutes of
Health] pathway" doing research requires mobilising large amounts of unrestricted funding
that can be hard to come by:
All your donors and your partners, all want lot of reporting and a lot of M&E stuff, but
nobody really wants to pay for it. (P1)
Often the last year of the program, people are scrambling so much for new money. . .I’m
being paid to analyse data. . .but [right now] I’m writing [funding] proposals. (P12)
One funder identified a funding gap as organisations grow:
I’d like to see kind of a funder continuum. . .it’s a valley of death once you get to be like a 5
or 8 million dollar a year organisation. . .everyone wants to give $100,000 or $250,000 but
no one wants to write a seven-figure check. (F10)
The lack of unrestricted funding for research makes it harder to train local staff (P9), attract
and retain qualified researchers (P14), build robust M&E platforms (P14), clean existing data
(P8, P14), and conduct rigorous trials and in-depth qualitative work (P6):
The ideal scenario is. . .if you look at any major tech company; they have an internal R&D
department. Justifying funding for that is not complicated because they make a lot of
money. Figuring out how to justify internal R&D departments at global health NGOs is
super important. (P6)
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Unrestricted or research-oriented funding must be made available to encourage robust
research.
4. Lean research and technical education. While several practitioners and funders
accused researchers of “misplaced precision” (F8) they also valued “rigorous” research. Practi-
tioners identified the need for “approaches to evaluation. . .readily off the shelf [that organisa-
tions could] use as tools to actually implement evaluation” (P10), smaller, “real-time” studies
that enable organisations to “course-correct” as they go (P12, F6), and cheaper evaluation
methods (P4).
When people talk about evidence-based decision making. . . A lot of the programme teams
don’t have that kind of analytic training. (P12)
Such components could form part of a toolkit that would enable practitioners to easily per-
form unobtrusive, light touch—“lean”—research in everyday practice. Though others cau-
tioned against re-inventing the wheel, noting that “a lot [of material] is already out there” (F2),
suggests that an essential complement to any toolkit must be education regarding how to
search for and understand existing strategies.
5. Creating accountability. A more profound and less easily operationalized suggestion
was given voice by one practitioner:
[We often say] we are doing things to “prove a model” etc. That presupposes that what
we’re doing already works and that we figured everything out and sometimes precludes
opportunities to really take measurement as our opportunity for learning and for account-
ability, because a lot of global health interventions fail and a lot of great ideas don’t end up
working out. (P2)
One funder noted, “organisations are not as. . .eager and willing to do a good job of imple-
menting a high-impact model that they did not themselves develop” (F1). Rather than believe
that individual organisations will solve any given problem, funders suggested that “most” prac-
titioners “don’t have all of the pieces” and so should think of themselves as part of a larger
team that should work together to solve a project (F6). While one practitioner mentioned her
organization actively encouraged the adoption of any program with similar goals and out-
comes (P13), the vast majority were focused on scaling their particular model. The ways in
which this individualistic, competitive climate is encouraged by the celebration of social entre-
preneurs and the conceptualization of social innovation in health as “a business” must be
considered.
Several policymakers were adamant that practitioners also needed to be held accountable
for making early and transparent contact with the MOH in their respective countries. As one
MOH representative from East Africa explained:
NGOs [should] come direct into the Ministry. . .presenting what they have and how this
could be integrated with what the government is doing. . . Continuously engaging with the
Ministry. . .is very important. Sometimes, [practitioners] go somewhere without informing
the Ministry and [do] something which is contrary to the . . . position of the Ministry. . .
which is a disaster. . .because that resource is simply spent in vain in something that the
Ministry doesn’t appreciate. (M2)
Ministries of Health must likewise be held accountable for creating an environment that
allows social innovation to flourish in their countries. This means proactively developing
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relationships with NGOs working in their countries to ensure alignment and create opportuni-
ties for collaboration and piloting new ideas. Moreover, as one funder asserts, “once some-
thing’s been proven with world-class research to work, the governments [should] free up
resources to actually implement [it]” (F10).
Funders recognize, however, that they too need to improve:
I think there’s a lot of bad behaviour on the funders’ side: when they do single year and
when they do restricted, when they take a lot of people’s time and make them jump through
all kinds of hoops and then don’t use the information at all for anything. (F10)
As one funder put it, “I don’t know if you can think of any foundation head who’s ever
been fired for lack of impact, so why would you even measure it if it isn’t really that impor-
tant?” (F1). One way of creating accountability for funders may be through the use of a priori
evidence standards. The Social Research Unit at Dartington (UK) offers a framework for evi-
dence standards based on questions around practicality, rigour, outcomes, side-effects and
replicability [20]. Their application has not been without difficulty–less than 4% of the initial
240 applications to one government program met the standards, indicating a lack of evidence-
based programmes from which funders and policymakers could choose. While it is possible to
disagree with the content of the standards, the fact that they exist proves that it is possible to
pursue impact in a transparent, rigorous fashion and have this vision adopted by governments,
funders, and implementers alike.
Conclusion
Thirty-two one-on-one interviews were conducted with purposively selected practitioners,
policymakers, and funders from LMICs to explore (a) beliefs and attitudes towards the value
of and types of evidence in scaling social innovations for health, (b) approaches to evidence
generation and evaluation used in systems and policy change, and (c) how better evidence-
generation can be undertaken and supported within social innovation in health.
While practitioners are largely convinced of the merits of rigorous research, they face sev-
eral barriers in undertaking it. A central tension is striking the right balance between rigor and
operational relevance; an issue compounded by the difficulty of finding accessible technical
expertise. Practitioners assert that funders and policymakers are more moved by stories or per-
sonal connections than rigorous counterfactuals, but these assumptions were not necessarily
borne out in decision-maker narratives. Though funders didn’t typically question or critically
appraise the evidence of effect with which they were presented, policymakers tended to be very
explicit about the types of evidence they valued when considering interventions as candidates
for scale. In several areas, funders and policy-makers align with practitioners.
One area where practitioners, funders, and policymakers converge is that few have given
systematic consideration to potential unintended consequences of the programmes they
implement, fund, or adopt. While a small number were open about harms, the vast majority
do not have rigorous systems in place to track harm, and a number are in denial that causing
harm is even possible.
By speaking with all groups concurrently we were able to convene a constructive discussion
and guide the identification of areas in which actionable strategies for improvement could be
generated. Those that emerged were: supporting the research efforts of emerging organisa-
tions; creating links between practitioners and academia; altering the funding landscape for
evidence-generation; providing responsive technical education; and creating accountability
for funders, practitioners, and policymakers.
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Strengths and weaknesses of the study
Only by fostering a conversation across the entire ecosystem of actors required to scale pro-
grams can entrenched issues be confronted in creative, mutually agreeable ways. This is the
first qualitative study to simultaneously explore practitioner, funder, and policymaker views
on evidence generation and scale. Three limitations of the study were (i) policymakers proved
more difficult to secure for interviews than expected and so theoretical saturation was not
reached for this group, (ii) researchers were not sampled as a separate group, despite emerging
as a major actor in the discussion, and (iii) the relatively short interviews time (~35 min aver-
age), while enabling a large and relatively diverse sample, meant less depth was achieved with
each participant. The credibility of this study was nonetheless enhanced by the use of multiple
analysts to independently code data and review interpretations.
Implications
The findings of this study highlight issues that are relevant to enabling better evidence genera-
tion and use in health by practitioners, funders and policymakers alike. Because this inquiry
pushed participants for specific, actionable suggestions, the “doing better” proposals provide
deep insights into evidence generation, understanding ‘pain points,’ and ideas for potential
solutions.
Better evidence is not a panacea—taking interventions to scale is a complex process that
requires the recognition of the importance of evidence in decision-making, understanding
between practitioners, funders and policy-makers and the use of a variety of evidence typolo-
gies. Nonetheless, how better evidence-generation can be undertaken and supported within
social innovation in health is a previously under-operationalised aspect of this process that
remains essential in order to refrain from causing harm, enables us to optimise existing inter-
ventions, and ultimately, to scale and fund only what works.
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